NEW YORK (360Dx) – Australian proteomics firm Proteomics International Laboratories said today it has licensed US sales of its PromarkerD test for diabetic kidney disease to PrismHealthDx (PHDx).

According to Proteomics International, Austin, Texas-based PHDx will roll out a national launch of the test, which uses mass spectrometry to measure blood-based proteins to predict diabetes patients' risk of developing diabetic kidney disease. PHDx will offer the test as a laboratory-developed test out of its CLIA facilities.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Feb
21
Sponsored by
L7 Informatics

This webinar will provide a first-hand look at how Gradalis, a clinical-stage immunotherapy developer, is using an information management solution from L7 to streamline its research, clinical, and manufacturing operations.

Feb
26
Sponsored by
Advanced Cell Diagnostics

This webinar will demonstrate how a research team at the Firestone Institute for Respiratory Health at McMaster University developed a cellular and molecular phenotyping pipeline using archived samples of lung tissue derived from patients diagnosed with fibrotic interstitial lung disease. 

Mar
20
Sponsored by
Qiagen

This webinar will discuss how a new multiplexed testing system can help physicians rapidly diagnose acute respiratory infections in the near-patient setting.